Constellation Pharmaceuticals CEO and leadership

Jigar Raythatha joined Jounce Therapeutics in December 2012 after a 15 year career in the biotechnology industry in a variety business functions. Most recently, Jigar Raythatha was the head of corporate development of Constellation Pharmaceuticals, Inc. where he was instrumental in securing over $175 million in non-dilutive and equity funding. In addition, Jigar Raythatha negotiated and subsequently led the company's broad epigenetics strategic alliance with Genentech and established Constellation's project management and market development capabilities. Prior to Constellation, Jigar Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal, and finally a venture partner. During his tenure at Red Abbey, Jigar Raythatha led or participated in all of the firm's investments, including Advanced BioHealing (acquired by Shire), Aegerion Pharmaceuticals (IPO), Cogenesys (acquired by Teva), and Stromedix (acquired by Biogen Idec). Previously, Jigar Raythatha has worked with Biogen, Inc. and Pfizer, Inc. in business development and new product planning roles. Jigar Raythatha holds an M.B.A. from Columbia Business School and a B.A. in molecular biology and biochemistry and economics from Rutgers University.

Mr. Joseph Collard W. is a Cofounder Chief Executive Officer at Constellation Pharmaceuticals and is based in United States.

Patrick Trojer is a Chief Scientific Officer at Constellation Pharmaceuticals. He has worked as Senior VP:Ezh2 Franchise/Head:Translational Sciences at Constellation Pharmaceuticals and VP/Head:Research at Constellation Pharmaceuticals. Patrick attended New York University School of Medicine and Leopold Franzens University.

Jeffrey Humphrey is a Chief Medical Officer at Constellation Pharmaceuticals and is based in Princeton, New Jersey. He has worked as Intern and Resident, Internal Medicine at Johns Hopkins; President, Chief Medical Officer at KYOWA KIRIN PHARMACEUTICAL DEVELOPMENT LIMITED; and Senior Vice President, Drug Development at Kyowa Kirin International. Jeffrey works or has worked as President, Chief Medical Officer at Kyowa Kirin International. He studied at Harvard University between 1979 and 1983 and CASE WESTERN RESERVE UNIVERSITY between 1983 and 1987.

A versatile, results oriented Human Resources leader with diverse hands-on experience in established and entrepreneurial organizations. Highly skilled at developing programs and processes to align human capital with strategic business objectives. Successful track record with merger integrations. Possess a decisive and equitable approach building positive, productive work environments.

Brendan Delaney is a Chief Commercial Officer at Constellation Pharmaceuticals and is based in Leonia, New Jersey. He has worked as Oncology Marketing at Novartis, Sales Representative at Bristol-Myers Squibb, and Sales Representative at Berlex Laboratories Inc.. Brendan studied at University of Virginia Darden School of Business, Rutgers University between 1992 and 1996, and Stern School Of Business between 2001 and 2003.

Mr. Joseph Collard W. is a Cofounder Chief Executive Officer at Constellation Pharmaceuticals and is based in United States.